NASDAQ:SAVA - Cassava Sciences Stock Price, Forecast & News

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SAVA shares have increased by 0.5% and is now trading at $4.26. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cassava Sciences.

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Cassava Sciences.

Cassava Sciences Inc (NASDAQ:SAVA) announced its earnings results on Thursday, March, 26th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. View Cassava Sciences' earnings history.

Cassava Sciences's stock reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

2 equities research analysts have issued twelve-month price objectives for Cassava Sciences' shares. Their forecasts range from $6.00 to $12.00. On average, they expect Cassava Sciences' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 111.3% from the stock's current price. View analysts' price targets for Cassava Sciences.

Media coverage about SAVA stock has been trending somewhat negative on Saturday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cassava Sciences earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutCassava Sciences.

Cassava Sciences saw a drop in short interest in February. As of February 28th, there was short interest totaling 1,190,000 shares, a drop of 17.4% from the February 13th total of 1,440,000 shares. Based on an average trading volume of 4,960,000 shares, the short-interest ratio is currently 0.2 days. Approximately 8.1% of the shares of the stock are short sold. View Cassava Sciences' Current Options Chain.

Some companies that are related to Cassava Sciences include Spectrum Pharmaceuticals (SPPI), Kala Pharmaceuticals (KALA), Avid Bioservices (CDMO), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Rigel Pharmaceuticals (RIGL), Passage Bio (IMRA), Ocular Therapeutix (OCUL), Bicycle Therapeutics (BCYC), Seres Therapeutics (MCRB), Kamada (KMDA), Syros Pharmaceuticals (SYRS), Arcturus Therapeutics (ARCT), Minerva Neurosciences (NERV) and Galera Therapeutics (GRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Baidu (BIDU), DURECT (DRRX), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Bristol-Myers Squibb (BMY), Amarin (AMRN) and TrovaGene (TROV).

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.90%), Geode Capital Management LLC (0.84%), Jefferies Group LLC (0.41%), Marshall Wace LLP (0.32%), Envestnet Asset Management Inc. (0.28%) and Cetera Advisor Networks LLC (0.12%). Company insiders that own Cassava Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, Eric Schoen, Remi Barbier and Sanford Robertson. View institutional ownership trends for Cassava Sciences.

SAVA stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Cassava Sciences.

SAVA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jefferies Group LLC, Geode Capital Management LLC, Marshall Wace LLP, Cetera Advisor Networks LLC, Acadian Asset Management LLC, and Jane Street Group LLC. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson. View insider buying and selling activity for Cassava Sciences.

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SAVA stock can currently be purchased for approximately $4.26.

Cassava Sciences has a market capitalization of $73.36 million. The company earns $-6,560,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe. View additional information about Cassava Sciences.

The official website for Cassava Sciences is http://www.cassavasciences.com/.

Cassava Sciences' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]